1
|
Moghaddam-Banaem L, Deilami-Nezhad L, Sadeghi M, Jalilifar M. DEVELOPMENT AND ESTIMATION OF HUMAN DOSIMETRY OF A NEW 47SC-RISEDRONATE FOR RADIOPHARMACEUTICAL APPLICATION. RADIATION PROTECTION DOSIMETRY 2022; 198:1483-1494. [PMID: 36156088 DOI: 10.1093/rpd/ncac190] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/02/2021] [Revised: 05/21/2022] [Accepted: 07/13/2022] [Indexed: 06/16/2023]
Abstract
Bisphosphonate risedronate (2-(3-pyridinyl)-1-hydroxyethane diphosphonic acid) was radiolabeled with scandium-47 (47Sc) as potential therapeutic radiopharmaceutical for skeletal metastases. Its time-dependent biodistribution in mice was measured and its human dosimetry was derived. The labelling process was performed at 95 °C for 30 min. The stability of the radio-conjugate was tested in human serum at 37 °C and its biodistribution was studied in balb/c mice. The radiochemical yield of ≥90% was obtained corresponding to a specific activity of 277 MBq/mg. The radio-conjugate showed good stability in human serum up to 48 h. A high bone uptake by 48 h post-injection was achieved, which suggests that 47Sc-risedronate may be therapeutically beneficial for the palliation of painful bone metastasis. The estimated absorbed dose coefficient and the time-integrated activity coefficient (ã (rs, TD)) in the bone were 1.35 mGy/MBq and 31.04 (Bq-h/Bq), respectively. The absorbed doses to non-osseous normal organs were much lower than that to the bone.
Collapse
Affiliation(s)
- Leila Moghaddam-Banaem
- Department of Isotopic separation, Nuclear Material and fuel School, Nuclear Science and Technology Research Institute, P.O. Box: 14155-1339, Tehran, Iran
| | - Leila Deilami-Nezhad
- Department of Medical Radiation Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Mahdi Sadeghi
- Medical Physics Department, School of Medicine, Iran University of Medical Sciences, P.O. Box: 14155-6183, Tehran, Iran
| | - Mostafa Jalilifar
- Medical Physics Department, School of Medicine, Iran University of Medical Sciences, P.O. Box: 14155-6183, Tehran, Iran
| |
Collapse
|
2
|
Moghaddam-Banaem L, Aghaei Amirkhizi N, Sadjadi S, Johari-Deha F, Athari-Allaf M. The Preparation, Biodistribution, and Dosimetry of Encapsulated Radio-Scandium in a Dendrimer for Radio-nano-pharmaceutical Application. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH 2022; 21:e126912. [PMID: 36060907 PMCID: PMC9420232 DOI: 10.5812/ijpr-126912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Revised: 01/09/2022] [Accepted: 01/23/2022] [Indexed: 11/16/2022]
Abstract
This study aimed to investigate the synthesis, characterization, and biodistribution of scandium nanoparticles encapsulated within poly (amidoamine) (PAMAM) dendrimers, as well as to estimate the human absorbed dose. It also aimed to examine, in particular, the amine-terminated PAMAM dendrimers in generation 5. Irradiation of the compound in the nuclear reactor resulted in the formation of Sc-radioactive complex nanoparticles. The compound of the dendrimer-Sc3+ was confirmed by the UV-vis spectrometer. The size of the particles was less than 10 nm, and it was assessed using high-resolution transmission electron microscopy (HRTEM) and dynamic light scattering (DLS). The synthesized complex was irradiated by the 3 × 1011 n.cm-2s-1 flux of neutron for 2 h. Mice bearing a breast tumor were employed to assess the therapeutic dose that was delivered by the poly scandium-46-nanoparticles. As opposed to the untreated groups, a single injection of poly phosphate-buffered saline to intratumoral in other groups to deliver a dose of 100 µCi resulted in a statistically significant 39.24% reduction in tumor volume 14 days after injection. After applying the biokinetics data in mice, the human’s absorbed dose from scandium-47 encapsulated PAMAM was extrapolated based on animal data. The absorbed doses in critical organs, including the liver, lung, spleen, kidney, and bone, were 0.879, 0.0472, 0.191, 0.107, and 0.155 mGy/MBq, respectively.
Collapse
Affiliation(s)
- Leila Moghaddam-Banaem
- Nuclear Fuel Cycle School, Nuclear Sciences and Technology Research Institute (NSTRI), Tehran, Iran
- Corresponding Author: Nuclear Fuel Cycle School, Nuclear Sciences and Technology Research Institute (NSTRI), Tehran, Iran.
| | - Navideh Aghaei Amirkhizi
- Radiation Application School, Nuclear Sciences and Technology Research Institute (NSTRI), Tehran, Iran
| | - Sodeh Sadjadi
- Radiation Application School, Nuclear Sciences and Technology Research Institute (NSTRI), Tehran, Iran
| | - Fariba Johari-Deha
- Radiation Application School, Nuclear Sciences and Technology Research Institute (NSTRI), Tehran, Iran
| | - Mitra Athari-Allaf
- Department of Medical Radiation Engineering, Sciences and Research Branch, Islamic Azad University, Tehran, Iran
| |
Collapse
|
3
|
Durán MT, Juget F, Nedjadi Y, Bochud F, Talip Z, van der Meulen NP, Köster U, Duchemin C, Stora T, Bailat C. Ytterbium-175 half-life determination. Appl Radiat Isot 2021; 176:109893. [PMID: 34425350 DOI: 10.1016/j.apradiso.2021.109893] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Accepted: 08/08/2021] [Indexed: 10/20/2022]
Abstract
175Yb is a radionuclide that can be generated by neutron capture on 174Yb and whose decay properties make it useful for developing therapeutic radiopharmaceuticals. As it happens with many of the emerging radionuclides for medical uses in recent years, its nuclear data were determined decades ago and are not thoroughly documented nor accurate enough for metrological purposes. The last documented reference for the 175Yb half-life value is 4.185(1) days and dates back to 1989, so a redetermination of the value was considered appropriate before standardization at the Institute of Radiation Physics (IRA, Lausanne, Switzerland) primary measurements laboratory. Three independent measurement methods were used to this purpose: reference ionization chamber (CIR, chambre d'ionization de référence), CeBr3 γ-ray detector with digital electronics and a second CeBr3 detector with analog electronics and single-channel analyzer (SCA) counting. The value obtained for the 175Yb half-life is 4.1615(30) days which shows a 0.56% relative deviation to the last nuclear reference value (ENSDF 2004) and is supported with a detailed calculation of the associated uncertainty.
Collapse
Affiliation(s)
| | | | | | | | - Zeynep Talip
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI, Switzerland
| | - Nicholas P van der Meulen
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI, Switzerland; Laboratory of Radiochemistry, Paul Scherrer Institute (PSI), Villigen-PSI, Switzerland
| | - Ulli Köster
- Institut Laue-Langevin (ILL), Grenoble, France
| | - Charlotte Duchemin
- European Organization for Nuclear Research (CERN), Geneva, Switzerland; KU Leuven, Instituut voor Kern-en stralingsfysica (IKS), B-3001 Leuven, Belgium
| | - Thierry Stora
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - Claude Bailat
- Institute of Radiation Physics, Lausanne, Switzerland
| |
Collapse
|
4
|
Swidan MM, Khowessah OM, El-Motaleb MA, El-Bary AA, El-Kolaly MT, Sakr TM. Iron oxide nanoparticulate system as a cornerstone in the effective delivery of Tc-99 m radionuclide: a potential molecular imaging probe for tumor diagnosis. ACTA ACUST UNITED AC 2019; 27:49-58. [PMID: 30706223 DOI: 10.1007/s40199-019-00241-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Accepted: 01/07/2019] [Indexed: 01/13/2023]
Abstract
BACKGROUND The evolution of nanoparticles has gained prominence as platforms for developing diagnostic and/or therapeutic radiotracers. This study aims to develop a novel technique for fabricating a tumor diagnostic probe based on iron oxide nanoparticles excluding the utilization of chelating ligands. METHODS Tc-99 m radionuclide was loaded into magnetic iron oxide nanoparticles platform (MIONPs) by sonication. 99mTc-encapsulated MIONPs were fully characterized concerning particles size, charge, radiochemical purity, encapsulation efficiency, in-vitro stability and cytotoxicity. These merits were biologically evaluated in normal and solid tumor bearing mice via different delivery approaches. RESULTS 99mTc-encapsulated MIONPs probe was synthesized with average particle size 24.08 ± 7.9 nm, hydrodynamic size 52 nm, zeta potential -28 mV, radiolabeling yield 96 ± 0.83%, high in-vitro physiological stability, and appropriate cytotoxicity behavior. The in-vivo evaluation in solid tumor bearing mice revealed that the maximum tumor radioactivity accumulation (25.39 ± 0.57, 36.40 ± 0.59 and 72.61 ± 0.82%ID/g) was accomplished at 60, 60 and 30 min p.i. for intravenous, intravenous with physical magnet targeting and intratumoral delivery, respectively. The optimum T/NT ratios of 57.70, 65.00 and 87.48 were demonstrated at 60 min post I.V., I.V. with physical magnet targeting and I.T. delivery, respectively. These chemical and biological characteristics of our prepared nano-probe demonstrate highly advanced merits over the previously reported chelator mediated radiolabeled nano-formulations which reported maximum tumor uptakes in the scope of 3.65 ± 0.19 to 16.21 ± 2.56%ID/g. CONCLUSION Stabilized encapsulation of 99mTc radionuclide into MIONPs elucidates a novel strategy for developing an advanced nano-sized radiopharmaceutical for tumor diagnosis. Graphical abstract 99mTc-encapsulated MIONPs nanosized-radiopharmaceutical as molecular imaging probe for tumor diagnosis.
Collapse
Affiliation(s)
- Mohamed M Swidan
- Labeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, PO13759, Cairo, Egypt.
| | - Omnya M Khowessah
- Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Cairo University, PO11562, Cairo, Egypt
| | - Mohamed Abd El-Motaleb
- Labeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, PO13759, Cairo, Egypt
| | - Ahmed Abd El-Bary
- Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Cairo University, PO11562, Cairo, Egypt
| | - Mohamed T El-Kolaly
- Labeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, PO13759, Cairo, Egypt
| | - Tamer M Sakr
- Radioactive Isotopes and Generator Department, Hot Labs Center, Egyptian Atomic Energy Authority, PO13759, Cairo, Egypt. .,Pharmaceutical Chemistry Department, Faculty of Pharmacy, Modern Sciences and Arts University, 6th October City, Egypt.
| |
Collapse
|
5
|
Aghaei-Amirkhizi N, Sadjadi S, Moghaddam-Banaem L, Athari-Allaf M, Johari-Deha F. Dosimetry of 175Ytterbium-poly (amidoamine) Therapy for Humans' Organs. J Med Phys 2018; 43:173-178. [PMID: 30305775 PMCID: PMC6172863 DOI: 10.4103/jmp.jmp_8_18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Purpose: This investigation focuses on biodistribution of irradiated dendrimer encapsulated ytterbium-175 (175Yb) and to estimate the absorbed dose from intravenous injection of PAMAM encapsulated 175Yb to human organs. Methods: A dendrimer compound containing an average of 55 Yb+3 ions per dendrimer was prepared and irradiated with neutrons for 2h at 3×1011 n.cm-2s-1 neutron flux. The resulting mixture was injected into a group of tumor bearing mice and the mice were excised, weighed and counted at certain times to study the biodistribution. The human organs absorbed dose was assessed by MIRD schema and MCNP simulation. Results: The specific activity and radiochemical purity of the irradiated nano-composite were 7MBq/mg and >99% respectively. The rapid up take of dendrimer was in liver, lung, and, spleen. MIRD and MCNPX were applied for dose estimation. The human absorbed dose in liver, lung, spleen, kidney and bone that simulated by MCNP are 1.266, 0.8081, 0.8347, 0.03979 and 0.01706 mGy/MBq respectively and these values for MIRD schema are 1.351, 0.73, 1.03, 0.039, and 0.0097 mGy/MBq respectively. Conclusion: The results showed that 175Yb-PAMAM nano-radiopharmaceutical has potential of application for liver and lung tumors.
Collapse
Affiliation(s)
- Navideh Aghaei-Amirkhizi
- Department of Medical Radiation Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran.,Department of Radiopharmacy and Radioisotopes Research, Applied of Radiation School, Nuclear Science and Technology Research Institute, Tehran, Iran
| | - Sodeh Sadjadi
- Department of Production and Separation of Isotopes, Nuclear Material and Fuel School, Nuclear Science and Technology Research Institute, Tehran, Iran
| | - Leila Moghaddam-Banaem
- Department of Production and Separation of Isotopes, Nuclear Material and Fuel School, Nuclear Science and Technology Research Institute, Tehran, Iran
| | - Mitra Athari-Allaf
- Department of Medical Radiation Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Fariba Johari-Deha
- Department of Radiopharmacy and Radioisotopes Research, Applied of Radiation School, Nuclear Science and Technology Research Institute, Tehran, Iran
| |
Collapse
|